Susquehanna International Group, LLP Syndax Pharmaceuticals Inc Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

26 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$17.93 - $24.81 $1.73 Million - $2.39 Million	96,500 Added 66.19%	242,300 $4.66 Million
Q2 2024 Aug 15, 2024	SELL	$18.82 - $23.79 $1.03 Million - $1.31 Million	-54,900 Reduced 27.35%	145,800 $2.99 Million
Q1 2024 May 07, 2024	BUY	$19.71 - $24.57 $1.41 Million - $1.76 Million	71,700 Added 55.58%	200,700 $4.78 Million
Q4 2023 Feb 14, 2024	SELL	$11.39 - $21.67 $5.11 Million - $9.71 Million	-448,300 Reduced 77.65%	129,000 $2.79 Million
Q3 2023 Nov 14, 2023	BUY	$14.52 - $21.77 $7.33 Million - $11 Million	504,900 Added 697.38%	577,300 $8.38 Million
Q2 2023 Aug 11, 2023	BUY	$19.35 - $22.31 $1.4 Million - $1.62 Million	72,400 New	72,400 $1.52 Million
Q4 2022 Feb 14, 2023	SELL	$20.64 - $26.24 $835,920 - $1.06 Million	-40,500 Reduced 47.76%	44,300 $1.13 Million
Q3 2022 Nov 14, 2022	BUY	$18.51 - $24.79 $9,255 - $12,395	500 Added 0.59%	84,800 $2.04 Million
Q2 2022 Aug 15, 2022	BUY	$13.64 - $19.48 $662,904 - $946,728	48,600 Added 136.13%	84,300 $1.62 Million
Q1 2022 May 16, 2022	SELL	$14.84 - $22.15 $216,664 - $323,390	-14,600 Reduced 29.03%	35,700 $620,000
Q4 2021 Feb 14, 2022	BUY	$15.23 - $22.47 $487,360 - $719,040	32,000 Added 174.86%	50,300 $1.1 Million
Q3 2021 Nov 15, 2021	SELL	$13.87 - $19.8 $238,564 - $340,560	-17,200 Reduced 48.45%	18,300 $350,000
Q2 2021 Aug 11, 2021	BUY	$13.42 - $25.18 $89,914 - $168,706	6,700 Added 23.26%	35,500 $610,000
Q1 2021 May 17, 2021	SELL	$19.28 - $24.59 $566,832 - $722,946	-29,400 Reduced 50.52%	28,800 $644,000
Q4 2020 Feb 16, 2021	BUY	$15.1 - $26.44 $277,840 - $486,496	18,400 Added 46.23%	58,200 $1.29 Million
Q3 2020 Nov 16, 2020	SELL	$13.39 - $17.48 $4.36 Million - $5.69 Million	-325,700 Reduced 89.11%	39,800 $587,000
Q2 2020 Aug 14, 2020	BUY	$8.94 - $20.98 $1.09 Million - $2.55 Million	121,400 Added 49.73%	365,500 $5.42 Million
Q1 2020 May 15, 2020	BUY	$6.65 - $12.03 $1.1 Million - $1.98 Million	164,900 Added 208.21%	244,100 $2.68 Million
Q4 2019 Feb 14, 2020	BUY	$5.43 - $9.22 $29,865 - $50,710	5,500 Added 7.46%	79,200 $695,000
Q3 2019 Nov 14, 2019	SELL	$7.47 - $10.76 $59,760 - $86,080	-8,000 Reduced 9.79%	73,700 $551,000
Q2 2019 Aug 14, 2019	BUY	$4.9 - $9.31 $180,320 - $342,608	36,800 Added 81.96%	81,700 $761,000
Q1 2019 May 15, 2019	BUY	$4.26 - $6.86 $121,836 - $196,196	28,600 Added 175.46%	44,900 $236,000
Q4 2018 Feb 14, 2019	SELL	$3.6 - $8.42 $360,000 - $842,000	-100,000 Reduced 85.98%	16,300 $73,000
Q3 2018 Nov 14, 2018	BUY	$6.33 - $8.08 $493,740 - $630,240	78,000 Added 203.66%	116,300 $940,000
Q2 2018 Aug 14, 2018	BUY	$6.93 - $14.63 $150,381 - $317,471	21,700 Added 130.72%	38,300 $269,000
Q1 2018 May 15, 2018	BUY	$8.71 - $14.82 $144,586 - $246,012	16,600 New	16,600 $236,000

Others Institutions Holding SNDX

# of Institutions

228

Shares Held

88.4M

Call Options Held

1.01M

Put Options Held

692K

Black Rock Inc. New York, NY

7.91M
Shares

$103 Million
0.0% of portfolio
Kynam Capital Management, LP Princeton, NJ

5.84M
Shares

$76.4 Million
9.23% of portfolio
Wellington Management Group LLP Boston, MA

4.99M
Shares

$65.2 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

4.89M
Shares

$63.9 Million
0.0% of portfolio
Eversept Partners, LP New York, NY

4.11M
Shares

$53.7 Million
6.25% of portfolio

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $740M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account